中华临床免疫和变态反应杂志2017，Vol.11Issue(2)：131-135,5.DOI:10.3969/j.issn.1673-8705.2017.02.006
肿瘤坏死因子抑制剂治疗难治性复发性多软骨炎的疗效并文献复习
Efficacy of Tumor Necrosis Factor Inhibitors on Relapsing Polychondritis:11 Refractory Cases and Review of Literature
姜楠 1袁娜 2王迁 1沈敏 1李梦涛 1曾小峰1
作者信息
- 1. 中国医学科学院 北京协和医学院 北京协和医院风湿免疫科 风湿免疫病学教育部重点实验室,北京 100730
- 2. 长春中医药大学附属医院风湿科,长春 130021
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of tumor necrosis factor-α (TNF-α) inhibitors for the treatment of refractory relapsing polychondritis.Methods Retrospectively analyzed the clinical manifestations, laboratory data and medications of 11 patients with refractory RP who were treated with TNF-α inhibitors in Peking Union Medical College Hospital between 2007 and 2016.The efficacy of TNF-α inhibitors were then assessed.Results One patient was treated with infliximab, 10 patients were treated with TNF-α soluble receptor fusion protein.Patients were treated with TNF-α inhibitors for 6 to 39 months, and were followed for 6 to 58 months.After the using of TNF-α inhibitors, the ESRs and CRPs were significantly decreased (P<0.05).FEV1s and FEV1/FVCs were increased, but the differences were not statistically significant.The Patients' and physicians' assessments indicated that the clinical condition of 7 patientswas improved, 3 patients were in stable in a relatively good status, 1 patient failed to response to the treatment and his disease was not controlled.The efficacy of TNF-α inhibitors was assessed as effective in 10 patients and ineffective in 1 patient.No adverse event was observed.Conclusion TNF-α inhibitors have good efficacy and safety in the treatment of refractory RP.But further investigations are required.关键词
复发性多软骨炎,难治性/生物制剂/肿瘤坏死因子抑制剂Key words
relapsing polychondritis/refractory/bioagent/tumor necrosis factor inhibitor分类
医药卫生引用本文复制引用
姜楠,袁娜,王迁,沈敏,李梦涛,曾小峰..肿瘤坏死因子抑制剂治疗难治性复发性多软骨炎的疗效并文献复习[J].中华临床免疫和变态反应杂志,2017,11(2):131-135,5.
